Real-World Studies
High BMI Predicts Improved Immunotherapy Response and Survival in Advanced Esophageal Cancer
Tan et alScientific Reports
PD-1 inhibitor-based immunotherapy is an established therapeutic strategy for locally advanced or metastatic esophageal cancer, but the influence of systemic metabolic factors on treatment responsiveness remains incompletely understood. To evaluate the "obesity paradox"—where higher body mass index (BMI) correlates with reduced mortality and improved immunotherapy outcomes—researchers conducted a study analyzing 286 eligible patients across two medical centers who received anti-PD-1 therapy. Patients were stratified by BMI and metabolic syndrome (MetS) status to evaluate survival metrics, treatment response, and underlying immune parameters.
Patients categorized with high BMI or MetS achieved significantly better overall survival, progression-free survival, and objective response rates compared to low-to-normal BMI cohorts. These metabolic profiles aligned with favorable immune metrics, notably lower pan-immune inflammation values (PIV) and elevated PD-L1 combined positive scores (CPS). Multivariable analysis indicated that elevated BMI serves as an independent predictor of favorable post-immunotherapy outcomes, whereas the prognostic signal associated with MetS was largely driven by body mass.
Utilizing LASSO and multivariable Cox regression, investigators developed a prognostic nomogram integrating four independent risk factors: gender, BMI, TNM stage, and PIV. The model demonstrated strong predictive accuracy for 24- and 36-month overall survival across both internal and external validation cohorts, supported by well-fitted calibration curves, offering clinicians a refined approach for risk stratification in advanced esophageal cancer.
Key Takeaways
- In a 286-patient study of locally advanced or metastatic esophageal cancer, high body mass index (BMI) and metabolic syndrome significantly correlated with superior overall survival, progression-free survival, and objective response rates following anti-PD-1 therapy.
- Patients with elevated BMI or metabolic syndrome exhibited favorable baseline immune profiles, characterized by reduced pan-immune inflammation values (PIV) and higher combined positive scores (CPS).
- A validated prognostic nomogram incorporating four independent predictors—gender, BMI, TNM stage, and PIV—accurately predicted 24- and 36-month overall survival in internal and external validation cohorts.
Read the original sourceScientific Reports
